AURKA and prostate cancer: Interestingly, Tozasertib/(VX-680) IC50 values against PANC1 and T-47D cells were 7.6 μM and 17.9 μM, respectively, implying that hit 85 (NCI 14040) possesses higher anti-proliferative activity as an Aurora-A kinase inhibitor than does the standard control; Tozasertib/(VX-680). Lastly, it was decided to test the hits showing activity against previous cell-lines on prostate cancer cells (i.e., PC-3).